利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.011 秒)

    COMPOSITIONS AND METHODS OF INHIBTING MASP-1 AND/OR MASP-3 FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    2.
    发明公开
    COMPOSITIONS AND METHODS OF INHIBTING MASP-1 AND/OR MASP-3 FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 有权
    组合物和用于抑制方法MASP-1和/或MASP-3用于治疗阵发性夜间血红蛋白尿

    公开(公告)号：EP2833907A4

    公开(公告)日：2016-03-16

    申请号：EP13798222

    申请日：2013-04-05

    申请人： OMEROS CORP ,  UNIV LEICESTER

    发明人： SCHWAEBLE HANS-WILHELM ,  DEMOPULOS GREGORY A

    IPC分类号： A61K39/00 ,  C07K16/40

    CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

    摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

    摘要翻译： 在一个方面，本发明提供方法和组合物用于抑制在从阵发性睡眠性血红蛋白尿症的受试者MASP-3依赖性补体活化通过给予受试者的组合物，其包括MASP-3抑制剂的量的有效抑制量 MASP-3依赖性补体活化。 在另一个方面，本发明提供了通过给受试者施用一种组合物，其包括MASP-1抑制剂中的至少一个和/或量的增加红血细胞在从阵发性睡眠性血红蛋白尿症的受治疗者的存活的方法和组合物 一个有效MASP-3抑制剂，以增加红血细胞的存活。 在一些实施方案中，受试者施用MASP-2抑制剂和MASP-1抑制剂，MASP-2抑制剂和施用MASP-3抑制剂，MASP-3抑制剂和MASP-1抑制剂 或MASP-1抑制剂，MASP-2抑制剂和MASP-3抑制剂。

    METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    6.
    发明公开
    METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION 审中-公开
    VFAFAHREN ZUR BEHANDLUNG VON LEIDEN IN ZUSAMMENHANG MIT MASP-2-ABHÄNGIGERKOMPLEMENTAKTIVIERUNG

    公开(公告)号：EP3057993A4

    公开(公告)日：2017-09-13

    申请号：EP14853910

    申请日：2014-10-17

    申请人： OMEROS CORP ,  UNIV LEICESTER

    发明人： DEMOPULOS GREGORY A ,  DUDLER THOMAS ,  SCHWAEBLE HANS-WILHELM

    IPC分类号： C07K16/40

    CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.

    摘要翻译： 一方面，本发明提供了抑制患有或有发生血栓性微血管病（TMA）风险的活体中MASP-2依赖性补体活化作用的方法。 该方法包括向有需要的受试者施用有效抑制MASP-2依赖性补体激活的量的MASP-2抑制剂的步骤。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化相关的细胞损伤，同时使免疫系统的经典（C1q依赖性）途径组分保持完整。

    METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    7.
    发明公开
    METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION 审中-公开
    VERFAHREN ZUR BEHANDLUNG AUSGEBREITETERINTRAVASKULÄRERGERINNUNG DURCH HEMMUNG MASP-2-ABHÄNGIGERKOMPLEMENTAKTIVIERUNG

    公开(公告)号：EP3150635A3

    公开(公告)日：2017-06-21

    申请号：EP16199359

    申请日：2010-10-15

    申请人： OMEROS CORP ,  UNIV LEICESTER

    发明人： SCHWAEBLE HANS-WILHELM ,  DUDLER THOMAS A ,  TEDFORD CLARK E ,  PARENT JAMES B ,  DEMOPULOS GREGORY A

    IPC分类号： C07K16/40

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C12Y304/21104

    摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

    摘要翻译： 一方面，本发明提供了抑制活体中MASP-2依赖性补体活化作用的方法。 在一个实施方案中，本发明提供了治疗患有补体介导的凝血病症（例如弥散性血管内凝血）的受试者的方法。 该方法包括向有需要的受试者施用有效抑制MASP-2依赖性补体激活的量的MASP-2抑制剂的步骤。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化相关的细胞损伤，同时保持免疫系统的经典（Clq依赖性）途径组分完整。 另一方面，本发明提供了用于抑制凝集素依赖性补体活化作用的组合物，其包含治疗有效量的MASP-2抑制剂和药学上可接受的载体。